

Nat Prod. Author manuscript; available in PMC 2010 November 19.

Published in final edited form as:

J Nat Prod. 2009 November; 72(11): 2043–2045. doi:10.1021/np900288x.

An Antimicrobial Guanidine-bearing Sesterterpene from the Cultured Cyanobacterium *Scytonema* sp

Shunyan Mo[†], Aleksej Krunic[†], Scott D. Pegan[‡], Scott G. Franzblau[§], and Jimmy Orjala^{*,†}
†Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, 833 S. Wood Street, Chicago, IL 60612

[‡]Center for Pharmaceutical Biotechnology, University of Illinois at Chicago, 900 S. Ashland Avenue, Chicago, IL 60607

§Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, 833 S. Wood Street, Chicago, IL 60612

Abstract

Scytoscalarol (1), a new antimicrobial sesterterpene bearing a guanidine group, was isolated from the cultured cyanobacterium Scytonema sp. (UTEX 1163) by bioassay-guided fractionation. The chemical structure was determined by spectroscopic analysis including MS, 1D and 2D NMR. Scytoscalarol (1) showed antimicrobial activities against Bacillus anthracis, Staphylococcus aureus, $Escherichia\ coli$, $Candida\ albicans$ and $Escherichia\ coli$, $Escherichia\ coli$

Cyanobacteria are a promising but underexplored source for biologically active secondary metabolites. ^{1,2} Numerous biologically active natural products have been reported from cyanobacteria, inclusive of alkaloids, polyketides, and linear as well as cyclic peptides. ¹⁻³ However, terpenes are not commonly found in cyanobacteria, and there are only a few reports of cyanobacterial terpenes. ⁴⁻⁷ In our search for antimicrobial compounds from cyanobacteria, a guanidine-bearing sesterterpene, scytoscalarol (1) was isolated from the cultured terrestrial cyanobacterium *Scytonema* sp. (UTEX 1163). Scytoscalarol (1) has a scalarane skeleton, a class of sesterterpenes commonly found in various species of marine sponges of the order Dictyoceratida. ⁸ Several scalarane sesterterpenes have been reported to exhibit significant cytotoxicity in human cancer cell lines ⁹ and antimicrobial activity against various microorganisms. ¹⁰ Scytoscalarol (1) is the first sesterterpene reported from cyanobacteria and the first guanidine-containing sesterterpene from a natural source. Herein, we reported the isolation, structural elucidation and biological activity of this compound.

Scytonema sp. was initially acquired from the Culture Collection of Algae at the University of Texas at Austin (UTEX 1163). In our screening, the crude extract of Scytonema sp. (UTEX 1163) was found to possess antibacterial activity against Bacillus anthracis (MIC 40 μ g/mL) and was mass cultured in the laboratory for chemical investigation. The antibacterial MeOH:CH₂Cl₂ extract was fractionated using a diaion HP20SS resin column and Scytoscalarol (1) was obtained as a precipitate from fraction 3. The structure was determined by interpretation of MS, 1D and 2D NMR data.

^{*}To whom correspondence should be addressed. Tel: 312-996-5583, Fax: 312-996-7107, orjala@uic.edu.

1

Scytoscalarol (1) was obtained as a white amorphous solid. The molecular formula was determined by HRMS as $C_{26}H_{45}N_3O_2$ (m/z 416.3651 [M+H] $^+$) and implied six degrees of unsaturation. Analysis of $^1H,\,^{13}C,\, COSY$ and HSQC NMR spectra suggested the presence of four isolated CHCH $_2$ CH $_2$ spin systems (C-1 to C-3, C-5 to C-7, C-9-C-11-C-12, and C-14 to C-16) and one CHCH $_2$ (C-18-C-25) spin system (Figure 1). Two proton resonances at δ_H 4.94 and 4.48 were assigned to an exomethylene moiety (C-24, δ_C 107.6). The 1H NMR spectrum also contained resonances for five isolated singlet methyl groups at δ_H 0.82, 0.85, 0.91, 0.88 and 0.77.

The 13 C NMR spectrum contained 26 carbon signals, three of which appeared above 100 ppm. Two of these were assigned to the exomethylene moiety (C-17 $\delta_{\rm C}$ 147.8 and C-24 $\delta_{\rm C}$ 107.6). The quaternary carbon at $\delta_{\rm C}$ 158.6 ppm was attributed to a guanidine group based on the chemical shift 11 as well as consideration of the molecular formula. Of the six degrees of unsaturation required by the molecular formula, two were accounted for by the exomethylene moiety and the guanidine group. Hence scytoscalarol (1) was deduced to be tetracyclic.

The planar structure of **1** was determined by analysis of HMBC data (Table 1 and Figure 1). The isolated CHCH₂CH₂ spin system from C-1 to C-3 was connected to the C-5 to C-7 spin system via a gem-dimethyl group at C-4 based on the correlations from both H₃-19 and H₃-20 to C-3 and C-5. HMBC correlations from H₃-21 to C-10, C-1, and C-5, as well as from H-5 to C-1 connected C-1 and C-5 to C 10 to form a six membered ring (A). HMBC correlations from H₃-21 to C-9 also connected the C-9-C-11-C-12 spin system to C-10. HMBC correlations from H₃-22 to C-8, C-9 and C-7 connected both C-7 and C-9 to C-8 and formed a second six membered ring (B). In addition, a correlation from H₃-22 to C-14 as well as from H-7_{ax} to C-14 indicated that the C-14 to C-16 spin system was also connected to C-8. HMBC correlations from H₃-23 to C-13, C-12 and C-14 completed ring C. Correlations from both H₃-23 and H-12_{ax} to C-18 placed C-18-C-25 spin system adjacent to C-13. The final ring (D) was deduced by HMBC correlations from H₂-24 to C-16, C-17 and C-18, thus connecting C-18 and C-16 via C-17 of the exomethylene group and establishing a tetracylic scalarene-type sesterterpene skeleton. The chemical shift of C-1 (δ_c 81.0) combined with one oxygen atom

required by the molecular formula, placed a hydroxy group at C-1. This was confirmed by a HMBC correlation from OH proton ($\delta_{\rm H}$ 4.04, observed in DMSO- d_6) to C-1. The guanidine moiety at C-25 was confirmed by a HMBC correlation from H₂-25 to the guanidine carbon C-2′, as well as the COSY correlation between NH-1′ and H₂-25.

The relative configuration was determined by analysis of the 2D NOESY spectrum (Figure 2 and Table 1). NOESY correlations observed between H-11_{ax} and H₃-21, H₃-22 and H₃-23 as well as between H₃-23 and H₂-25 indicated all these groups to be in the β plane. This led to the determination of the relative configuration as 8*S**, 10*S** and 13*S**. Correlations between H-9 and both H-5 and H-14 indicated H-5, H-9 and H-14 all to be in the α plane. NOESY correlations between H-5 and H-1, as well as between H-14 and H-18 indicated H-1 and H-18 to be in the α plane as well and determined the relative configuration as 1*R**, 5*S**, 9*S**, 14*S** and 18*S**. The rings A, B, C and D were all-*trans* and the relative configuration of scytosclarol was determined as 1*R**, 5*S**, 8*S**, 9*S**, 10*S**, 13*S**, 14*S** and 18*S** as shown above.

Scytoscalarol (1) has a scalarane skeleton and showed antimicrobial activity against *Bacillus anthracis* (MIC 6 μ M), *Staphylococcus aureus* (MIC 2 μ M), *Escherichia* coli (MIC 30 μ M), *Candida albicans* (MIC 4 μ M) and *Mycobacterium tuberculosis* (MIC 110 μ M). Scytoscalarol was also weakly cytotoxic (IC₅₀ 135 μ M) in a Vero cell assay.

This is the first report of a scalarane sesterterpene from cyanobacteria. Scalaranes represent a common class of sesterterpenes found in various species of marine sponges of the order Dictyoceratida. S,12 12-keto-scalarane derivatives have also been found in sponge-feeding *Glossodoris* nudibranchs. It was assumed that certain *Glossodoris* nudibranchs can produce these compounds by enzymatic oxidation of dietary scalaranes. A biosynthetic study of scalarane sesterterpenes suggested that this class of compounds might be of microbial origin. Several previously reported metabolites from sponges have been found to be produced by symbiotic microorganism. However, there are no reports of the cyanobacterium *Scytonema* associated with sponges of the order Dictyoceratida. More research is needed to determine if cyanobacteria are involved in the production of the scalarane-type sesterterpenoids in marine sponges.

Scytoscalarol (1) is the first guanidine-bearing sesterterpene isolated from natural sources. Many guanidine-containing polyketide, peptides and alkaloids have been reported from terrestrial, freshwater and marine microganisms and invertebrates. ¹⁶ Most reports of cyanobacterial guanidine bearing compounds are from arginine-containing linear or cyclic peptides as well as alkaloids. ³ Some terpenoid guanidine alkaloids have been identified from higher plants, such as the galegines from *Galega officinalis* ¹⁷ and pterogynidine and the nitensidines from *Pterogyne nitens*. ^{18,19}

Experimental Section

General experimental procedures

The optical rotation was determined on a Perkin-Elmer 241 polarimeter. IR spectra were obtained on a Jasco FTIR-410 Fourier transform infrared spectrometer. $^1\mathrm{H}$ and $^{13}\mathrm{C}$ NMR spectra were obtained on a Bruker Avance AVII900 MHz NMR spectrometer with 5mm ATM CPTCI Z-gradient probe, referenced to the corresponding solvent peaks. Low resolution ESI mass spectra were obtained on a ThermoFinnigan TSQuantum Triple Quadrupole Mass Spectrometer. High resolution ESI mass spectra were obtained on a Thermo Electron LTQ-FT-ICR mass spectrometer.

Biological Material

Scytonema sp., a terrestrial cyanobacterium, was acquired from the Culture Collection of Algae at the University of Texas at Austin (UTEX 1163). The cyanobacterium was grown in 13 L of aerated inorganic media (Z media). Cultures were illuminated with fluorescent lamps at 1.93 klx with an 18/6 h light/dark cycle. The temperature of culture room was maintained at 22° C. After 4 weeks, the biomass of cyanobacteria was harvested by centrifugation and freeze-dried.

Extraction and isolation—The freeze-dried biomass (2.88 g) was extracted by repeated maceration with CH₂Cl₂:MeOH (1:1) to yield 597.6 mg of crude extract. The crude extract showed inhibitory activity against *B. anthracis* (MIC 40 μ g/mL). A portion of crude extract (572 mg) was fractionated on a diaion HP20SS column using a gradient with increasing amount of isopropanol in water to afford 9 fractions. Fraction 3 (eluted with 40% isopropanol) was the most active fraction against both *B. anthracis* (MIC 2.5 μ g/mL) and *M. tuberculosis* (MIC 10.8 μ g/mL). A white amorphous powder precipitated from fraction 3 upon drying under air flow. The precipitate was purified by filtration to afford 1 (15.4 mg).

Scytoscalarol (1)—white amorphous powder; $[\alpha]_D$ +6 (c 0.41 MeOH); IR (neat) v_{max} 3341, 3189, 2935, 2848, 1666, 1388, 1339, 1035 cm⁻¹; 1H NMR and ^{13}C (see Table 1); HRESIMS m/z 416.3651 [M+H]⁺ (calcd for $C_{26}H_{46}N_3O$, 416.3641).

Antimicrobial Assays—*Bacillus anthracis*. The fractions and compound **1** were tested with concentrations from 100 µg/mL to 48.8 ng/mL using the previously described method. ²¹ The minimal inhibitory concentration (MIC) sample was calculated as the lowest concentration that prevents visible bacterial growth. *Mycobacterium tuberculosis*. The inhibitory activity of fractions and compound **1** against *M. tuberculosis* was performed using the Microplate Alamar blue Assay (MABA). ²² Virulent H37Rv strain was used in the assay. The MIC value was determined as the lowest sample concentration effecting an inhibition of \geq 90%. *Other organisms*. The broth microdilution MIC method was used to test the activity of **1** against bacteria ²³ and *Candida albicans*. ²⁴

Cytotoxicity

The cytotoxicity of **1** was evaluated using green monkey kidney cells (Vero).²⁵ Cell viability was measured using the CellTiter 96 aqueous nonradioactive cell proliferation assay.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Dr. S. Cho, B. Wan, Y. Wang, D. Wei, B. Becker and K. Sidell from the Institute for Tuberculosis Research (ITR) at UIC for performing antibacterial, antifungal and cytotoxicity assays and Dr. A. Mesecar at UIC for *B. anthracis* data. We also thank Dr. C. A. Crot from the Research Resources Center (RRC) at UIC for high resolution mass spectrometry. The 900 MHz NMR spectrometer was funded by NIH P41 grant GM68944. This research was supported by NIH grant R01GM0758556.

References and Notes

- 1. Williams PG. Trends Biotechnol 2009;27:45-52. [PubMed: 19022511]
- 2. Tan LT. Phytochemistry 2007;68:954–979. [PubMed: 17336349]
- 3. Van Wagoner, RM.; Drummond, AK.; Wright, JLL. Advances in Applied Microbiology. Laskin, AI.; Sariaslani, S.; Gadd, GM., editors. Elsevier; San Diego: 2007. p. 89-217.
- 4. Smith JL, Boyer GL, Zimba PV. Aquaculture 2008;280:5-20.

- 5. Jaki B, Heilmann J, Sticher O. J Nat Prod 2000;63:1283-1285. [PubMed: 11000038]
- Jaki B, Orjala J, Heilmann J, Linden A, Vogler B, Sticher O. J Nat Prod 2000;63:339–343. [PubMed: 10757714]
- 7. Jaki B, Orjala J, Sticher O. J Nat Prod 1999;62:502–503. [PubMed: 10096870]
- 8. Liu Y, Wangb L, Jungc JH, Zhanga S. Nat Prod Rep 2007;24:1401–1429. [PubMed: 18033586]
- 9. Wen-Jian Lan H-JL. Helv Chim Acta 2007;90:1218–1222.
- 10. Song J, Jeong W, Wang N, Lee H-S, Sim CJ, Oh K-B, Shin J. J Nat Prod 2008;71:1866-1871.
- 11. Cho JY, Williams PG, Kwon HC, Jensen PR, Fenical W. J Nat Prod 2007;70:1321–1328. [PubMed: 17630797]
- 12. Gavagnin M, Mollo E, Docimo T, Guo Y-W, Cimino G. J Nat Prod 2004;67:2104–2107. [PubMed: 15620263]
- 13. Manzo E, Gavagnin M, Somerville MJ, Mao S-C, Ciavatta ML, Mollo E, Schupp PJ, Garson MJ, Guo Y-W, Cimino G. J Chem Ecol 2007;33:2325–2336. [PubMed: 18000710]
- 14. Renoux JM, Rohmer M. Eur J Biochem 1986;155:125-132. [PubMed: 3081345]
- 15. Arillo A, Bavestrello G, Burlando B, Sarà M. Mar Biolog 2004;117:159–162.
- 16. Berlinck RGS, Burtoloso ACB, Kossuga MH. Nat Prod Rep 2008;25:919-954. [PubMed: 18820759]
- 17. Schaefer J, Stein M. Biol Zentralbl 1969;88:755-768.
- Regasini LO, Castro-Gamboa I, Silva DHS, Furlan M, Barreiro EJ, Ferreira PMP, Pessoa C, Lotufo LVC, de Moraes MO, Young MCM, Bolzani VDS. J Nat Prod 2009;72:473

 –476. [PubMed: 19159272]
- 19. Bolzani VDS, Gunatilaka AAL, Kingston DGI. J Nat Prod 1995;58:1683-1688.
- 20. Mian P, Heilmann J, Bürgi HR, Sticher O. Pharm Biol 2003;41:243.
- 21. Athamna A, Athamna M, Abu-Rashed N, Medlej B, Bast DJ, Rubinstein E. J Antimicrob Chemother 2004;54:424–428. [PubMed: 15205405]
- 22. Falzari K, Zhu Z, Pan D, Liu H, Hongmanee P, Franzblau SG. Antimicrob Agents Chemother 2005;49:1447–1454. [PubMed: 15793125]
- Isenberg, HD., editor. Clinical microbiology procedures handbook. Vol. 1. American Society for Microbiology; Washington D.C.: 2002.
- 24. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. NCCLS document M38-A; Wayne, PA: 2002.
- 25. Cantrell CL, Lu T, Fronczek FR, Fischer NH, Adams LB, Franzblau SG. J Nat Prod 1996;59:1131–1136. [PubMed: 8988597]




Figure 1. Key COSY and HMBC correlations of scytoscalarol (1)

Figure 2. Key NOESY correlations of scytoscalarol (1)

Mo et al.

Table 1

NMR data of Scytoscalarol (1) in MeOD- d_4 ^a

Position	δ _C , mult.	δ _H , mult., J(Hz)	COSY	HMBCb	NOE
	81.0, CH	3.32, m	Н-2, ОН	9, 10, 21	H-2 _{eq} , 3 _{ax} , 5, 9, 11
$2_{\rm ax}$ $2_{\rm eq}$	$30.3, \mathrm{CH}_2$	1.69, ddd (12.7, 11.8, 3.8) 1.57, m	H-1, 3	1, 3	H-3, 19, 21 H-1, 20
$3_{\rm ax}$ $3_{\rm eq}$	$41.1, CH_2$	1.29, ddd (12.7, 12.7, 3.8) 1.38, m	Н-3	1	H-1, 5, 20 H-19
4	34.0, qC				
5	56.4, CH	0.81, dd (11.8, 2.7)	9-H	1, 9, 10, 19, 20, 21	H-1, 3_{ax} , 9, 20
9	19.6, CH ₂	1.54, m	H-5, 7	5, 7, 10	H-19, 20
7 _{ax} 7 _{eq}	43.2, CH ₂	0.95, ddd (12.7, 12.5, 4.5) 1.79, d (12.7)	9-Н	5, 8, 9, 14, 22	H-14 H-22
8	40.1, qC				
6	63.2, CH	1.06, d (10.7)	H-11	1, 10, 11, 12, 21, 22	H-1, 5, 11 _{eq} , 12 _{ax} , 14
10	44.8, qC				
11 _{ax}	$21.6, \mathrm{CH}_2$	1.50, m 2.63. d (12.7)	Н-9, 12	13	H-21, 22, 23 H-9
ha.					
$12_{\rm ax}$ $12_{\rm eq}$	42.1, CH ₂	1.33, ddd (13.3, 12.7, 3.6) 1.83, d (12.7)	H-11	11, 13, 18, 23	H-9, 11 _{eq} , 18 H-11 _{ax} , 23, 25
13	40.0, qC				
14	61.6, CH	1.16, dd (12.1, 1.1)	H-15	8, 13,18, 23	H-7, 9, 16 _{ax} , 18
15 _{ax} 15 _{eq}	24.1, CH ₂	1.37, m 1.76, m	H-14, 16	13, 14, 17	H-22, 23, 24 H-14
16 _{ax}	38 6 CH.	2.04, ddd (12.7, 12.7, 4.4)	11	71 21 71 71 71 71	H-14 (strong)
$16_{\rm eq}$	36.0, CH2	2.44, d (12.0)	CI-II	14, 13, 17, 10, 24	H-14 (weak), 24
17	147.8, qC				
18	57.3, CH	1.96, d (10.3)	H-19	16, 17, 23, 24, 25	H-12 _{eq} , 14, 24, 25
19	$21.5, CH_3$	0.82, s		3, 4, 5, 20	H-2 _{ax} , 3 _{eq}
20	$33.3, CH_3$	0.85, s		3, 4, 5, 19	$H-2_{eq}, 3_{ax}, 5$

Page 8

NIH-PA Author Manuscript

Position	δ_{C} , mult.	Position $\delta_{\rm C}$, mult. $\delta_{\rm H}$, mult., $J({\rm Hz})$	COSY	HMBC^b	NOE
21	13.0, CH ₃ 0.91, s	0.91, s		1, 9, 5, 10	H-2 _{ax} , 11 _{ax}
22	18.3, CH ₃	0.88, s		7, 8, 9, 14	$H-7_{eq}$, 11_{ax} , 15_{ax} , 23
23	$16.1, \mathrm{CH}_3$	0.77, s		12, 13, 14, 18	$H-11_{ax}$, 12_{eq} , 15_{ax} , 24, 25
7	107 6 011	4.94, s		0 - 1	$\mathrm{H} ext{-}16_{\mathrm{eq}}$
7 7	107.0, CH ₂	4.49, s		16, 17, 18	$H-15_{ax}$, 23, 25
ų	20 O CH	3.38, d (10.3)	0, 11	70 07	H-12 _{eq} , 18
C7	30.0, CH ₂	3.22, t (11.6)	N-10	17, 18, 2	H-24
$_{c}$ HO		4.04 , d $(5.0)^C$	$H-1^C$	$1, 2, 10^c$	H-19, 21^{C}
NH-1'C		6.94, s ^c	$H-25^{C}$		H-18, 24, NH ₂ -3' and 4'c, d
2,	158.6, qC				
$NH_2-3^{\prime}c,d$		7.29 , brs c , d			$ m NH-1^{\prime c}$
$NH_2-4^{\prime}c,d$		6.60, brs^c , d			$^{ m NH-1}^{\prime c}$

 a Frequency: 900 MHz for 1 H and 226 MHz for 13 C

 $\ensuremath{^{b}}\xspace$ HMBC correlations are from proton(s) stated to the indicated carbon(s).

^{c1}H, COSY, HMBC and NOESY data of both hydroxy and guanidine groups were observed in the NMR spectra acquired in DMSO-d6. The complete NMR data in DMSO-d6 is included in the Supporting Information.

 $d_{\mbox{\sc Assignments}}$ of proton signals of the guanidine zwitterion may be reversed.